Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4051
AMES National
ATLO
$287M
| $317K | ﹤0.01% |
13,806
-2,076
| -13% | -$44.6K |
2022 Q4
12 quarters
|
|
4052
Neurogene
NGNE
$513M
| $317K | ﹤0.01% |
15,375
+448
| +3% | +$11.2K |
2024 Q1
7 quarters
|
|
4053
Epsilon Energy
EPSN
$174M
| $317K | ﹤0.01% |
68,241
+1,640
| +2% | +$7.91K |
2024 Q3
5 quarters
|
|
4054
Utah Medical Products
UTMD
$235M
| $314K | ﹤0.01% |
5,619
+908
| +19% | +$52.6K |
2020 Q2
22 quarters
|
|
4055
TechTarget
TTGT
$258M
| $314K | ﹤0.01% |
58,204
+16,375
| +39% | +$88.1K |
2016 Q1
39 quarters
|
|
4056
NACCO Industries
NC
$274M
| $314K | ﹤0.01% |
6,406
+614
| +11% | +$28.2K |
2022 Q2
14 quarters
|
|
4057
ReposiTrak
TRAK
$147M
| $314K | ﹤0.01% |
25,364
+2,614
| +11% | +$37.1K |
2023 Q3
9 quarters
|
|
4058
AlTi Global
ALTI
$335M
| $314K | ﹤0.01% |
67,567
+7,011
| +12% | +$28.9K |
2022 Q1
15 quarters
|
|
4059
Richmond Mutual Bancorp
RMBI
$248M
| $313K | ﹤0.01% |
22,283
+304
| +1% | +$4.17K |
2022 Q1
15 quarters
|
|
4060
Benitec Biopharma
BNTC
$313M
| $313K | ﹤0.01% |
23,211
+1,928
| +9% | +$26.7K |
2025 Q2
2 quarters
|
|
4061
CALL
Rio Tinto
RIO
$153B
| $312K | ﹤0.01% |
3,900
+2,900
| +290% | +$209K |
2025 Q3
1 quarter
|
|
4062
Sony
SONY
$139B
| $310K | ﹤0.01% |
12,118
-7,388
| -38% | -$207K |
2013 Q2
50 quarters
|
|
4063
GrafTech
EAF
$246M
| $310K | ﹤0.01% |
20,000
+19,685
| +6,249% | +$299K |
2018 Q2
30 quarters
|
|
4064
Arcturus Therapeutics
ARCT
$370M
| $310K | ﹤0.01% |
50,589
-31,363
| -38% | -$339K |
2019 Q3
25 quarters
|
|
4065
Aspen Aerogels
ASPN
$472M
| $310K | ﹤0.01% |
109,528
+10,163
| +10% | +$52.4K |
2020 Q2
22 quarters
|
|
|
WYFI
4066
WhiteFiber Inc
WYFI
$697M
| $309K | ﹤0.01% |
19,559
+9,641
| +97% | +$238K |
2025 Q3
1 quarter
|
|
4067
dLocal
DLO
$4.04B
| $308K | ﹤0.01% |
21,803
+21,732
| +30,608% | +$307K |
2025 Q3
1 quarter
|
|
4068
OmniAb
OABI
$708M
| $306K | ﹤0.01% |
165,557
+21,847
| +15% | +$38K |
2022 Q4
12 quarters
|
|
|
KDKRW
4069
Kodiak AI Warrants
KDKRW
| $306K | ﹤0.01% |
+200,000
| New | +$307K |
2025 Q4
0 quarters
|
|
4070
Fate Therapeutics
FATE
$278M
| $303K | ﹤0.01% |
308,542
+98,055
| +47% | +$118K |
2017 Q1
35 quarters
|
|
4071
CALL
UBS Group
UBS
$146B
| $301K | ﹤0.01% |
+6,500
| New | +$263K |
2025 Q4
0 quarters
|
|
|
PXED
4072
Phoenix Education Partners
PXED
$905M
| $301K | ﹤0.01% |
+9,925
| New | +$333K |
2025 Q4
0 quarters
|
|
4073
Shinhan Financial Group
SHG
$36.6B
| $300K | ﹤0.01% |
5,592
+4,536
| +430% | +$239K |
2025 Q3
1 quarter
|
|
|
CLPR
4074
Clipper Realty
CLPR
$50.7M
| $300K | ﹤0.01% |
78,487
+2,105
| +3% | +$7.86K |
2019 Q1
27 quarters
|
|
4075
Larimar Therapeutics
LRMR
$307M
| $299K | ﹤0.01% |
78,470
+7,577
| +11% | +$29.5K |
2023 Q1
11 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.